108 related articles for article (PubMed ID: 11218805)
1. Immunology of gangliosides.
Ravindranath MH; Gonzales AM; Nishimoto K; Tam WY; Soh D; Morton DL
Indian J Exp Biol; 2000 Apr; 38(4):301-12. PubMed ID: 11218805
[TBL] [Abstract][Full Text] [Related]
2. Human antiganglioside autoantibodies: validation of ELISA.
Ravindranath MH; Muthugounder S; Saravanan TS; Presser N; Morton DL
Ann N Y Acad Sci; 2005 Jun; 1050():229-42. PubMed ID: 16014538
[TBL] [Abstract][Full Text] [Related]
3. Significance of endogenous augmentation of antiganglioside IgM in cancer patients: potential tool for early detection and management of cancer therapy.
Ravindranath MH; Muthugounder S; Hannah MR; Morton DL
Ann N Y Acad Sci; 2007 Jun; 1107():212-22. PubMed ID: 17804549
[TBL] [Abstract][Full Text] [Related]
4. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies.
Zhang G; Lopez PH; Li CY; Mehta NR; Griffin JW; Schnaar RL; Sheikh KA
Brain; 2004 May; 127(Pt 5):1085-100. PubMed ID: 14985267
[TBL] [Abstract][Full Text] [Related]
5. Suppression of Ehrlich ascites tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype of the anti-GT1b IgM.
Saha S; Mondal S
Indian J Exp Biol; 2000 Dec; 38(12):1207-16. PubMed ID: 11411041
[TBL] [Abstract][Full Text] [Related]
6. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM.
Ravindranath MH; Wood TF; Soh D; Gonzales A; Muthugounder S; Perez C; Morton DL; Bilchik AJ
Cryobiology; 2002 Aug; 45(1):10-21. PubMed ID: 12445546
[TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
8. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal IgM autoantibody activity vis-à-vis glycoconjugates of peripheral nerves: apropos of 112 cases].
Caudie C; Vial C; Petiot P; Bancel J; Lombard C; Gonnaud PM
Ann Biol Clin (Paris); 2001; 59(5):567-77. PubMed ID: 11602387
[TBL] [Abstract][Full Text] [Related]
10. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy.
Halstead SK; O'Hanlon GM; Humphreys PD; Morrison DB; Morgan BP; Todd AJ; Plomp JJ; Willison HJ
Brain; 2004 Sep; 127(Pt 9):2109-23. PubMed ID: 15289269
[TBL] [Abstract][Full Text] [Related]
11. [Gangliosides as carbohydrate antigens associated with cancer and their possible use in tumor immunotherapy].
Horwacik I
Przegl Lek; 2004; 61 Suppl 2():14-9. PubMed ID: 15686040
[TBL] [Abstract][Full Text] [Related]
12. Subacute demyelinating polyneuropathy in B-cell lymphoma with IgM antibodies against glycolipid GD1b.
Marfia GA; Pachatz C; Terracciano C; Leone G; Bernardini S; Bernardi G; Massa R
Neurol Sci; 2005 Dec; 26(5):355-7. PubMed ID: 16388373
[TBL] [Abstract][Full Text] [Related]
13. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
14. Innate murine B cells produce anti-disialosyl antibodies reactive with Campylobacter jejuni LPS and gangliosides that are polyreactive and encoded by a restricted set of unmutated V genes.
Boffey J; Nicholl D; Wagner ER; Townson K; Goodyear C; Furukawa K; Furukawa K; Conner J; Willison HJ
J Neuroimmunol; 2004 Jul; 152(1-2):98-111. PubMed ID: 15223242
[TBL] [Abstract][Full Text] [Related]
15. Sulfatide binding properties of murine and human antiganglioside antibodies.
Townson K; Greenshields KN; Veitch J; Nicholl D; Eckhardt M; Galanina O; Bovin N; Samain E; Antoine T; Bundle D; Zhang P; Ling CC; Willison HJ
Glycobiology; 2007 Nov; 17(11):1156-66. PubMed ID: 17855742
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression by YAC-1 lymphoma: role of shed gangliosides.
Lu P; Sharom FJ
Cell Immunol; 1996 Oct; 173(1):22-32. PubMed ID: 8871598
[TBL] [Abstract][Full Text] [Related]
17. [Antiganglioside autoantibody profiles in Guillain-Barré syndrome].
Caudie C; Vial C; Bancel J; Petiot P; Antoine JC; Gonnaud PM
Ann Biol Clin (Paris); 2002; 60(5):589-97. PubMed ID: 12368145
[TBL] [Abstract][Full Text] [Related]
18. Glycosphingolipid antigens in neural tumor cell lines and anti-glycosphingolipid antibodies in sera of patients with neural tumors.
Ariga T; Suetake K; Nakane M; Kubota M; Usuki S; Kawashima I; Yu RK
Neurosignals; 2008; 16(2-3):226-34. PubMed ID: 18253060
[TBL] [Abstract][Full Text] [Related]
19. [Antiganglioside antibodies: when, which and for what].
Gallardo E; Rojas-García R; Belvís R; Serrano-Munuera C; Ortiz E; Ortiz N; Grau J; Illa I
Neurologia; 2001; 16(7):293-7. PubMed ID: 11485721
[TBL] [Abstract][Full Text] [Related]
20. Carbohydrate antigens as targets for active specific immunotherapy.
Ragupathi G
Cancer Immunol Immunother; 1996 Nov; 43(3):152-7. PubMed ID: 9001568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
